On November 11, 2025 Oncotelic Therapeutics Inc. (OTLC) and JV partner Sapu Bioscience reported the publication of their landmark review article, "Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential," in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; View Source) .
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, the paper is the first comprehensive review to systematically examine nanoparticles strictly within the 5-15 nm size domain-a scale that is now emerging as the most transformative scale in nanomedicine.
Defining a New Size Regime in Nanomedicine
While most clinical nanodrugs today rely on carriers between 50 nm and 200 nm, this review highlights how ultrasmall nanoparticles below 15 nm demonstrate fundamentally distinct biological behavior.
These sub-15 nm systems exhibit:
Deeper tissue and tumor penetration, reaching desmoplastic or poorly vascularized regions that larger nanocarriers cannot access;
Reduced reticuloendothelial accumulation and rapid renal clearance, minimizing long-term organ toxicity;
Enhanced diffusion across biological barriers, including the blood-brain barrier; and
Quantum-scale surface properties enabling multifunctional imaging and therapeutic applications.
This nanoscale window represents a new pharmacological paradigm where therapeutic delivery, tissue penetration, and clearance kinetics can be simultaneously optimized-offering the potential to overcome limitations of both small molecules and traditional nanocarriers.
A Platform for the Next Generation of Precision Therapies
"Sub-15 nm nanoparticles are not just smaller versions of conventional nanomedicines-they behave as an entirely new class of therapeutic entities," said Saran Saund, CBO of Oncotelic Therapeutics. "They open the door to safer, smarter, and more selective cancer treatments capable of crossing biological barriers that have limited drug delivery for decades."
Dr. Tapas De, Director of NanoFormulation at Oncotelic and lead author, added:
"Our analysis reveals that this ultrasmall size range achieves an optimal balance between deep tumor diffusion and systemic safety.
It’s the same size regime where nature’s own biomolecules-like antibodies and enzymes-operate most effectively."
Impact on Sapu’s Nanomedicine Pipeline
The findings directly inform the Sapu Deciparticle platform, including Sapu-003, an intravenous everolimus nanomedicine currently preparing for first-in-human evaluation.
"Publishing this comprehensive review validates the foundation of our Deciparticle technology," said Saran Saund, CBO of Oncotelic.
"Our ability to manufacture highly stable nanoparticles below 15 nm will be key to unlocking new therapeutic frontiers-from oncology to neurological and immune disorders."
About the Publication
Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential
Authors: Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi (Oncotelic Therapeutics); Saran Saund, Cynthia Lee (Sapu Bioscience)
Journal: International Journal of Molecular Sciences (ISSN 1422-0067)
DOI: 10.3390/ijms262210842
Published: November 8, 2025
(Press release, Oncotelic, NOV 11, 2025, View Source [SID1234659760])